Q-omics provides the consensus-scored CHRND profile across patient tissues and cancer cell-line models. CHRND expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CHRND is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CHRND RNA expression shows 12,018 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KIRC, and TGCT as cancer lineages where CHRND shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRND — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRND survival associations across molecular data types. CHRND RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRND RNA expression–survival associations across cancer types. High CHRND expression shows unfavorable associations in LIHC, HNSC, LGG, CESC, KIRC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for CHRND RNA expression.
This table summarizes CHRND tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CHRND. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRND shows higher tumor expression in KIRC, LUSC, COAD, UCEC, LUAD and BLCA. The KIRC box plot shows higher CHRND RNA expression in tumor versus normal tissue (log2 FC = +0.207, t-test p < 0.001).
This table shows molecular features associated with CHRND in patient tissues and cancer cell lines. In patient samples, CHRND shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRND RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
